The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)

被引：3

作者：

Kadowaki, S. ^{[1
]}

Sakai, D. ^{[2
]}

Kawabata, R. ^{[3
]}

Hara, H. ^{[4
]}

Yasui, H. ^{[5
]}

Takahashi, M. ^{[6
]}

Hirao, M. ^{[7
]}

Imai, H. ^{[8
]}

Minashi, K. ^{[9
]}

Kawakami, T. ^{[10
]}

Satake, H. ^{[11
]}

Matsuyama, J. ^{[12
]}

Sakamoto, Y. ^{[13
]}

Sawada, K. ^{[14
]}

Kataoka, M. ^{[15
]}

Kawakami, H. ^{[16
]}

Shimokawa, T. ^{[17
]}

Boku, N. ^{[18
]}

Satoh, T. ^{[19
]}

机构：

[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[2] Osaka Int Canc Inst, Dept Med Oncol, Osaka, Japan

[3] Osaka Rosai Hosp, Dept Gastrointestinal Surg, Sakai, Osaka, Japan

[4] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan

[5] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan

[6] Yokohama Municipal Citizens Hosp, Dept Gatroenterol Surg, Yokohama, Kanagawa, Japan

[7] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan

[8] Tohoku Univ Hosp, Dept Med Oncol, Sendai, Miyagi, Japan

[9] Chiba Canc Ctr Hosp, Clin Trial Promot Dept, Chiba, Japan

[10] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan

[11] Kansai Med Univ Hosp, Canc Treatment Ctr, Hirakata, Osaka, Japan

[12] Higashiosaka City Med Ctr, Dept Gastroenterol Surg, Higashiosaka, Osaka, Japan

[13] Osaki Citizen Hosp, Dept Med Oncol, Osaki, Japan

[14] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Japan

[15] Nagoya Med Ctr, Natl Hosp Org, Dept Surg, Nagoya, Aichi, Japan

[16] Kindai Univ, Dept Med Oncol, Fac Med, Osakasayama, Japan

[17] Wakayama Med Univ, Clin Study Support Ctr, Fac Med, Wakayama, Japan

[18] Univ Tokyo, Inst Med Sci, IMS Hosp, Dept Oncol & Gen Med, Tokyo, Kanagawa, Japan

[19] Osaka Univ Hosp, Ctr Canc Genom & Precis Med, Suita, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.077

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA76

引用

页码：S1317 / S1318

页数：2

共 50 条

[1] An intergroup phase III trial of ramucirumab plus irinotecan in third or more line beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial).
Sakai, Daisuke
Boku, Narikazu
Kodera, Yasuhiro
Komatsu, Yoshito
Fujii, Masashi
Iwasa, Satoru
Oki, Eiji
Koizumi, Wasaburo
Gamoh, Makio
Muro, Kei
Shimokawa, Toshio
Satoh, Taroh
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] HGCSG 1603: A phase 2 trial of ramucirumab plus irinotecan as second-line treatment for advanced gastric cancer
Sawada, Kentaro
Kawamoto, Yasuyuki
Yuki, Satoshi
Nakamura, Michio
Muto, Osamu
Sogabe, Susumu
Shindo, Ysohiaki
Ishiguro, Atsushi
Sato, Atsushi
Tsuji, Yasushi
Dazai, Masayoshi
Okuda, Hiroyuki
Sasaki, Takahide
Harada, Kazuaki
Nakano, Shintaro
Nakatsumi, Hiroshi
Sekiguchi, Mari
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
ANNALS OF ONCOLOGY, 2021, 32 : S314 - S314
[3] Results of a phase II trial of ramucirumab plus irinotecan as second-line treatment for patients with advanced gastric cancer (HGCSG 1603)
Kawamoto, Yasuyuki
Yuki, Satoshi
Sawada, Kentaro
Nakamura, Michio
Muto, Osamu
Sogabe, Susumu
Shindo, Yoshiaki
Ishiguro, Atsushi
Sato, Atsushi
Tsuji, Yasushi
Dazai, Masayoshi
Okuda, Hiroyuki
Sasaki, Takahide
Harada, Kazuaki
Nakano, Shintaro
Nakatsumi, Hiroshi
Sekiguchi, Mari
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[4] Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial
Sato, Yasuyoshi
Yamashita, Hiroharu
Yagi, Koichi
Nomura, Sachiyo
Seto, Yasuyuki
ANTICANCER RESEARCH, 2024, 44 (07) : 3125 - 3131
[5] Updated results of HGCSG1603: A phase 2 trial of ramucirumab plus irinotecan combination therapy as second-line treatment for patients with advanced gastric cancer
Nakamura, M.
Kawamoto, Y.
Yuki, S.
Sawada, K.
Muto, O.
Sogabe, S.
Shindo, Y.
Ishiguro, A.
Sato, A.
Tsuji, Y.
Dazai, M.
Okuda, H.
Sasaki, T.
Harada, K.
Nakatsumi, H.
Iuchi, K.
Sakata, Y.
Komatsu, Y.
ANNALS OF ONCOLOGY, 2021, 32 : S131 - S131
[6] Results of a phase 2 trial of ramucirumab plus docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
Sawada, Kentaro
Kawamoto, Yasuyuki
Harada, Kazuaki
Ando, Takayuki
Sogabe, Susumu
Kobayashi, Yoshimitsu
Dazai, Masayoshi
Nakamura, Michio
Hatanaka, Kazuteru
Ishiguro, Atsushi
Sato, Atsushi
Nakano, Shintaro
Shindo, Yoshiaki
Hosokawa, Ayumu
Ito, Ken
Yoshikawa, Ayumu
Iuchi, Kayoko
Yokota, Isao
Yuki, Satoshi
Komatsu, Yoshito
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 447 - 447
[7] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Taroh Satoh
Kyung Hee Lee
Sun Young Rha
Yasutsuna Sasaki
Se Hoon Park
Yoshito Komatsu
Hirofumi Yasui
Tae-You Kim
Kensei Yamaguchi
Nozomu Fuse
Yasuhide Yamada
Takashi Ura
Si-Young Kim
Masaki Munakata
Soh Saitoh
Kazuto Nishio
Satoshi Morita
Eriko Yamamoto
Qingwei Zhang
Jung-mi Kim
Yeul Hong Kim
Yuh Sakata
Gastric Cancer, 2015, 18 : 824 - 832
[8] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
Satoh, Taroh
Lee, Kyung Hee
Rha, Sun Young
Sasaki, Yasutsuna
Park, Se Hoon
Komatsu, Yoshito
Yasui, Hirofumi
Kim, Tae-You
Yamaguchi, Kensei
Fuse, Nozomu
Yamada, Yasuhide
Ura, Takashi
Kim, Si-Young
Munakata, Masaki
Saitoh, Soh
Nishio, Kazuto
Morita, Satoshi
Yamamoto, Eriko
Zhang, Qingwei
Kim, Jung-mi
Kim, Yeul Hong
Sakata, Yuh
GASTRIC CANCER, 2015, 18 (04) : 824 - 832
[9] Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
Kawamoto, Yasuyuki
Yuki, Satoshi
Sawada, Kentaro
Nakamura, Michio
Muto, Osamu
Sogabe, Susumu
Shindo, Yoshiaki
Ishiguro, Atsushi
Sato, Atsushi
Tsuji, Yasushi
Dazai, Masayoshi
Okuda, Hiroyuki
Meguro, Takashi
Harada, Kazuaki
Sekiguchi, Mari
Okada, Kazufumi
Ito, Yoichi M.
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
ONCOLOGIST, 2022, 27 (08): : E642 - E649
[10] Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)
Higuchi, Katsuhiko
Tanabe, Satoshi
Shimada, Ken
Hosaka, Hisashi
Sasaki, Eisaku
Nakayama, Norisuke
Takeda, Yuiti
Moriwaki, Toshikazu
Amagai, Kenji
Sekikawa, Takashi
Sakuyama, Toshikazu
Kanda, Tatsuo
Sasaki, Tohru
Azuma, Mizutomo
Takahashi, Fumiaki
Takeuchi, Masahiro
Koizumi, Wasaburo
EUROPEAN JOURNAL OF CANCER, 2014, 50 (08) : 1437 - 1445

← 1 2 3 4 5 →